Promising combo for prostate cancer halted early

NCT ID NCT02555189

Terminated Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at adding ribociclib to the standard hormone therapy enzalutamide for men with a certain type of advanced prostate cancer that had spread and no longer responded to hormone therapy alone. The goal was to find the best dose and see if the combination could lower PSA levels. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE CARCINOMA PROSTATE CARCINOMA METASTATIC IN THE BONE STAGE IV PROSTATE CANCER AJCC V7

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States